MetaDeq Diagnostics

Executive Summary

MetaDeq Diagnostics is a UK-based company developing HeparDx, a blood test for the early detection and monitoring of metabolic dysfunction-associated steatohepatitis (MASH) and liver fibrosis. The test specifically targets lobular inflammation and hepatocyte ballooning, key histological features of MASH. The company was founded in 2021 and is positioned to address a significant unmet need, especially following the American Diabetes Association's 2023 recommendation that all type 2 diabetes patients be screened for MASLD. While still in early stages, MetaDeq's focus on non-invasive diagnostics aligns with growing demand for alternatives to liver biopsy. The company has not disclosed funding or valuation, indicating a pre-revenue, development-stage profile. If successful, HeparDx could capture part of the large at-risk population, but execution risks remain high.

Upcoming Catalysts (preview)

• Q1 2027Completion of pivotal clinical validation study for HeparDx60% success
• Q2 2027FDA breakthrough device designation or CE marking initiation50% success
• Q3 2026Strategic partnership or licensing deal with a larger diagnostics or pharma company40% success